Efficacy of a Systematic Referral to Palliative Care of Patients Who Need for Palliative Care During an Unscheduled Visit in Comprehensive Anticancer Centers
Launched by CENTRE LEON BERARD · Nov 27, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how effective it is to refer cancer patients to a palliative care team when they visit the emergency room unexpectedly. Palliative care focuses on improving the quality of life for patients with serious illnesses by managing pain and other symptoms, even when the illness is not curable. In this study, some patients will continue to receive standard care, while others will be referred to the palliative care team right away.
To participate, individuals must be at least 18 years old, have a confirmed cancer diagnosis, and be admitted to the emergency room for an unexpected issue related to their cancer or treatment. They should also have a score indicating they need additional support (PALLIA-10 score greater than 3 out of 10). Patients will be asked to sign consent forms and must have medical insurance. Throughout the trial, participants can expect to receive either regular care or additional support from the palliative care team, helping them manage their symptoms and improve their overall well-being during a challenging time.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female ≥ 18 years at the day of consenting to the study;
- • Confirmed diagnosis of any type of solid or haematology tumours, with or without Current oncological treatment, such as chemotherapy, immunotherapy, targeted therapy, etc;
- • Unscheduled admission in a French Regional Comprehensive Anti-Cancer Centre due to an acute, unpredictable, intercurrent event related to cancer, its therapies or a comorbidity;
- • Patient for whom disease is considered as not curable;
- • PALLIA-10 Score \> 3/10;
- • Willingness and ability to comply with the study requirements;
- • Signed and dated informed consent indicating that the patient has been informed of all the aspects of the trial prior to enrolment;
- • Patient must be covered by a medical insurance.
- Exclusion Criteria:
- • Patient without consciousness, unable to provide a written informed consent (context of emergency);
- • Patient treated with a curative intent;
- • Previous randomization in this clinical study;
- • Patients already followed-up by a palliative care team;
- • Life expectancy shorter than 1 month, as per the emergency units' staff judgement.
- • Any medical or psychosocial condition that would compromise the patient's compliance to the study visits or would likely interfere with the completion of Patient-Reported Outcomes.
- • Patients under tutorship or curatorship.
About Centre Leon Berard
Centre Léon Bérard is a leading cancer research and treatment center located in Lyon, France, dedicated to advancing oncology through innovative clinical trials and comprehensive patient care. As a prominent institution in the field of cancer management, it integrates cutting-edge research, multidisciplinary expertise, and state-of-the-art facilities to enhance therapeutic outcomes and improve the quality of life for patients. The center is committed to fostering collaboration among researchers, healthcare professionals, and industry partners to drive the development of novel treatments and to contribute significantly to the global understanding of cancer.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Villejuif, , France
Lyon, , France
Vandœuvre Lès Nancy, , France
Paris, , France
Villejuif, île De France, France
Montpellier, , France
Saint Cloud, , France
Patients applied
Trial Officials
Gisèle CHVETZOFF, MD,PhD
Principal Investigator
Centre Leon Berard
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported